Adverse effects
Common side effects of Odevixibat include diarrhea, stomach pain, vomiting, abnormal liquid function tests, and a deficiency in vitamins A,D, E and K.

Contraindications
Odevixibat cannot be given to a child on a liquid diet. Society and culture
Legal status
In May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for odevixibat for the treatment of PFIC in people aged six months or older. It was approved for medical use in the European Union in July 2021. References
External links
"Odevixibat". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03566238 for "This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC 1 or 2 (PEDFIC 1)" at ClinicalTrials.gov
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohns disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.Common side effects include headache, nausea, abdominal pain, and fever. Serious side effects may include pericarditis, liver problems, and kidney problems. Use in pregnancy and breastfeeding appears safe. In people with a sulfa allergy certain formulations may result in problems. Mesalazine is an aminosalicylate and anti-inflammatory. It works by direct contact with the intestines.Mesalazine was approved for medical use in the United States in 1987. It is on the World Health Organizations List of Essential Medicines. It is available as a generic medication and sold under many brand names worldwide. In 2019, it was the 229th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Medical uses
It is used to treat inflammatory bowel disease, including ulcerative colitis and Crohns disease (effective only in colonic diseases). It is generally used for mildly to moderately active disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective. Side effects
There are no data on use in pregnant women, but the drug does cross the placenta and is excreted in breast milk.